Mauna Kea Technologies SA (ALMKT) Fair Value & Analysis
Healthcare · FR · Market cap €34.6M
Fair value as of: Jun 26, 2026
Analysis
Mauna Kea Technologies SA (ALMKT) currently trades at €0.1600, while our model-based Fair Value estimate is €0.9500 — implying the stock looks roughly 493.8% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
About the company
Mauna Kea Technologies SA manufactures and sells medical devices in Europe and internationally. It offers a range of medical devices for gastroenterology, pulmonology, and urology applications. Its product portfolio includes Cellvizio, a real-time in vivo cellular imaging platform that enables unique in vivo cellular visualization, allowing doctors to monitor disease evolution over time, evaluate reactions as they occur, classify areas of uncertainty, guide surgical interventions, and help diagnose and treat patients. The company was incorporated in 2000 and is headquartered in Paris, France.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Mauna Kea Technologies SA (ALMKT) undervalued?
What is the fair value of ALMKT?
What is the quality score of ALMKT?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.